KFDA to evaluate risk of cardiovascular events with sibutramine

The Korea Food and Drug Administration says it is reviewing final data from a recent study (SCOUT) suggesting that patients using sibutramine have a higher number of cardiovascular events than patients receiving placebo.

The study findings highlight the importance of avoiding the use of sibutramine in patients with a history of coronary artery disease, congestive heart failure (CHF), arrhyth...